# Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

> **NCT05784688** · PHASE1,PHASE2 · RECRUITING · sponsor: **TiumBio Co., Ltd.** · enrollment: 140 (estimated)

## Conditions studied

- Solid Tumor
- Biliary Tract Cancer
- Head and Neck Squamous Cell Carcinoma
- Colorectal Cancer

## Interventions

- **DRUG:** TU2218 + KEYTRUDA® (Pembrolizumab)

## Key facts

- **NCT ID:** NCT05784688
- **Lead sponsor:** TiumBio Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-10
- **Primary completion:** 2026-12
- **Final completion:** 2028-12
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05784688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05784688, "Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05784688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*